AUTHOR=Olivares Gerard , Sharman Mellora , Miller Rachel , Kisielewicz Caroline , Seth Mayank 

TITLE=Use of tranexamic acid in dogs with primary immune thrombocytopenia: A feasibility study

JOURNAL=Frontiers in Veterinary Science

VOLUME=Volume 10 - 2023

YEAR=2023

URL=https://www.frontiersin.org/journals/veterinary-science/articles/10.3389/fvets.2023.946127

DOI=10.3389/fvets.2023.946127

ISSN=2297-1769

ABSTRACT=<sec><title>Objective</title><p>The aim of this feasibility study is to evaluate the use of tranexamic acid and its safe use alongside standard therapy in dogs with primary immune thrombocytopenia (ITP).</p></sec><sec><title>Design</title><p>This is a cohort feasibility study involving 10 dogs diagnosed with primary ITP that received standard therapy for ITP including corticosteroids, a single dose of vincristine, and omeprazole. Dogs were randomly divided into either the control group (<italic>n</italic> = 6) or the group receiving tranexamic acid (TXA group, <italic>n</italic> = 4).</p></sec><sec><title>Key findings</title><p>The mean time from the start of treatment until remission was 5 days in the TXA group and 6 days in the control group (<italic>P</italic> = 0.69). Two dogs, one in each group, did not achieve remission. Clinical bleeding scores were not significantly different between both groups (<italic>p</italic> = 0.43), and the median blood volume administered was 37.5 ml/kg for the TXA group and 9.72 ml/kg for the control group (<italic>p</italic> = 0.084). Three out of the four dogs receiving TXA of 20 mg/kg IV started vomiting within 15 min of administration and were given a reduced dose of 15 or 10 mg/kg IV.</p></sec><sec><title>Conclusion</title><p>Tranexamic acid did not confer a clinical benefit in this small cohort study and was associated with a high incidence of vomiting. This study provides useful information for the design of future trials in dogs with ITP receiving tranexamic acid including outcome measures and safety.</p></sec>